Wird geladen...
Looking forward to new targeted treatments for chronic spontaneous urticaria
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing t...
Gespeichert in:
| Veröffentlicht in: | Clin Transl Allergy |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223554/ https://ncbi.nlm.nih.gov/pubmed/28078079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0139-2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|